{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:01:10Z","timestamp":1772730070160,"version":"3.50.1"},"reference-count":20,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen EOOD"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/16078454.2026.2631213","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:46:52Z","timestamp":1771487212000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-2825","authenticated-orcid":false,"given":"Georgi","family":"Mihaylov","sequence":"first","affiliation":[{"name":"Specialized Hospital for Active Treatment of Hematology Diseases, University Hospital","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Ianakieva","sequence":"additional","affiliation":[{"name":"Amgen Bulgaria EOOD","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1589-1280","authenticated-orcid":false,"given":"Zornitsa","family":"Katrandzhieva","sequence":"additional","affiliation":[{"name":"Sqilline Health Bulgaria","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiyan","family":"Karaasenov","sequence":"additional","affiliation":[{"name":"Sqilline Health Bulgaria","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7811-162X","authenticated-orcid":false,"given":"Veselina","family":"Goranova-Marinova","sequence":"additional","affiliation":[{"name":"Section of Hematology and Clinic of Hematology, Medical University of Plovdiv, University Hospital \u201cSv. Georgi\u201d","place":["Plovdiv, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"e_1_3_9_2_1","unstructured":"International Agency for Research on Cancer. Fact sheet Eastern Europe 2022 [Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/923-eastern-europe-fact-sheet.pdf."},{"key":"e_1_3_9_3_1","unstructured":"International Agency for Research on Cancer. Fact sheet Bulgaria 2022 [Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/100-bulgaria-fact-sheet.pdf."},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"issue":"1","key":"e_1_3_9_5_1","first-page":"30","article-title":"A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents","volume":"6","author":"Ria R","year":"2013","unstructured":"Ria R, Reale A, Moschetta M, et al. A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents. Int J Clin Exp Med. 2013;6(1):30\u201338.","journal-title":"Int J Clin Exp Med"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126208"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2018.100215"},{"issue":"4","key":"e_1_3_9_9_1","first-page":"285","article-title":"Myeloma bone disease: pathogenesis and treatment","volume":"15","author":"O'Donnell EK","year":"2017","unstructured":"O'Donnell EK, Raje NS. Myeloma bone disease: pathogenesis and treatment. Clin Adv Hematol Oncol. 2017;15(4):285\u2013295.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3090.3090"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh141"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6596-y"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.11.008"},{"key":"e_1_3_9_17_1","unstructured":"European Medicines Agency. Xgeva(R) (denosumab) \u2013 Summary of product characteristics: European Medicines Agency ; 2022 [updated 25 July 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf."},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1606002"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2017.56.02.09"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30559-3"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30072-x"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2026.2631213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:01:18Z","timestamp":1772726478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2026.2631213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/16078454.2026.2631213"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2026.2631213","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2631213"}}